These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15878322)

  • 1. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
    Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
    Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Semin Thromb Hemost; 1996; 22(3):255-9. PubMed ID: 8836010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
    Elg M; Gustafsson D
    Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
    Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
    Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
    Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin and factor Xa enhance neutrophil chemoattractant production after ischemia/reperfusion in the rat liver.
    Yamaguchi Y; Okabe K; Liang J; Ohshiro H; Ishihara K; Uchino S; Zhang JL; Hidaka H; Yamada S; Ogawa M
    J Surg Res; 2000 Jul; 92(1):96-102. PubMed ID: 10864488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
    Meddahi S; Samama MM
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
    Hérault JP; Perrin B; Jongbloet C; Pflieger AM; Bernat A; Herbert JM
    Thromb Haemost; 2000 Oct; 84(4):668-74. PubMed ID: 11057868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
    Elg M; Börjesson I; Carlsson S
    Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
    Akahane K; Okamoto K; Kikuchi M; Todoroki H; Higure A; Ohuchida T; Kitahara K; Takeda S; Itoh H; Ohsato K
    Surgery; 2001 Nov; 130(5):809-18. PubMed ID: 11685190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.